Alpha 2.0
Login Register
» Authors » Atalanta Ghosh

Atalanta Ghosh

Explore the profile of Atalanta Ghosh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 379
Followers 0
Related Specialties
Pharmacology
Endocrinology
Oncology
Top 10 Co-Authors
Paul Rothenberg
David Polidori
Sue Sha
Robert D Johnson
Sudha S Shankar
Xiaomin Wang
Roberto A Calle
David A Fryburg
Ralph H Raymond
Jane E Latz
Published In
Cancer Chemother Pharmacol
PLoS One
Adv Ther
Eur J Heart Fail
Cardiovasc Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cheng Y, Wang X, Ghosh A, Pu J, Carayannopoulos L, Li Y
J Clin Pharmacol . 2024 Apr; 64(8):984-992. PMID: 38563070
As a selective and potent inhibitor targeting the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib obtained approval from the US Food and Drug Administration (FDA) in 2017 for adult patients with...
2.
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
Cheng Y, Ye Y, Gaudy A, Ghosh A, Xue Y, Wang A, et al.
Clin Pharmacol . 2023 Mar; 15:9-19. PMID: 36880014
Introduction: Iberdomide, a novel cereblon modulator (CELMoD), is currently under clinical investigation for hematology indications. To evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of iberdomide and its...
3.
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants
Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, et al.
Clin Pharmacol Drug Dev . 2022 Oct; 11(12):1394-1404. PMID: 36256505
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received...
4.
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
Popmihajlov Z, Sutherland D, Horan G, Ghosh A, Lynch D, Noble P, et al.
BMJ Open Respir Res . 2022 Jan; 9(1). PMID: 35058236
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal interstitial lung disease (ILD); other ILDs have a progressive, fibrotic phenotype (PF-ILD). Antifibrotic agents can slow but not stop...
5.
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
Tran J, Zhang P, Walker S, Ghosh A, Syto M, Wang X, et al.
Adv Ther . 2020 Oct; 37(12):4944-4958. PMID: 33025342
Introduction: The aims of this study were to characterize the multiple-dose pharmacokinetics (PK) of ozanimod's major active metabolites (CC112273 and CC1084037) and to evaluate the pharmacodynamic and PK interactions with...
6.
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study
Tran J, Zhang P, Ghosh A, Liu L, Syto M, Wang X, et al.
Adv Ther . 2020 Aug; 37(10):4381-4395. PMID: 32857315
Introduction: The aims of this study were to characterize the single-dose pharmacokinetics (PK) of the major active metabolites of ozanimod, CC112273 and CC1084037, and to evaluate the effect of gemfibrozil...
7.
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, et al.
Diabetes Obes Metab . 2018 Nov; 21(4):812-821. PMID: 30447037
Aim: To evaluate the impact of the sodium glucose co-transporter 2 inhibitor canagliflozin on intrahepatic triglyceride (IHTG) accumulation and its relationship to changes in body weight and glucose metabolism. Materials...
8.
Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis
Wilson S, Connolly T, Peters G, Ghosh A, Johnson M, Newby D
Cardiovasc Res . 2018 Sep; 115(3):669-677. PMID: 30184110
Aims: JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, highly specific, large molecule, exosite 1 thrombin inhibitor. In preclinical studies, JNJ-9375 demonstrated robust antithrombotic protection with a wider therapeutic index when compared...
9.
Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function
Ruetten H, Gebauer M, Raymond R, Calle R, Cobelli C, Ghosh A, et al.
Metab Syndr Relat Disord . 2018 Aug; 16(8):406-415. PMID: 30117761
Background: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and...
10.
Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function
Shankar S, Lee D, Raymond R, Calle R, Cobelli C, Ghosh A, et al.
Contemp Clin Trials Commun . 2018 Jul; 10:94-99. PMID: 30023442
Results: Baseline characteristics were well-matched. Between and within subject variance for each parameter across cohorts, and intraclass correlation coefficients (ICC-a measure of reproducibility) across parameters were generally comparable for OP...